The types of assessments used as primary, and key secondary, endpoints in Alzheimer's trials are complex and therefore subject to error in administration. Improving signal-to-noise ratio is critical. It is common to see error in administration from physicians with less trial experience as well as variation in administration from country to country. The continuous, in-trial, monitoring of assessments to look for error is a critical part of improving the signal-to-noise ratio in complex global trials.
Cogstate had the pleasure of co-authoring a poster presented at #ADPD24 highlighting learnings from a rater performance monitoring program used in TRAILBLAZER-ALZ 2, a Phase 3 Clinical Trial of Donanemab in Early Symptomatic Alzheimer Disease. Rater performance was analyzed across four outcome measures that were part of the study and frequently leveraged in AD clinical trials: ♦️ ADAS-Cog 13 ♦️ ADCS-ADL ♦️ CDR ♦️ MMSE Poster co-author and Cogstate scientist, Dr. Svenja Wacker, shares the FINDINGS in this video 👉 https://lnkd.in/ejBsu4dp
